escal quickli guidanc
perfect storm pressur drive expect shortfal
multitud factor impact outlook creat on-going
neg feedback loop stock hard break quarter
bad back tax spike relat cordi continu pressur across
medic segment stunt profit growth opportun dynam outlin
reinstat report commentari rel pharma growth path howev
wors fear custom repric reduc view gener
deflat stabil contribut modest ep growth outlook despit
tax benefit contribut medtron patient recoveri acquisit
stock trade histor rang account factor well
uncertainti rest rx suppli chain also trade discount
valuat prefer name clearer pathway profit growth least fewer
profit headwind therefor reiter under-perform rate reduc
price object po
follow earn neg guidanc commentari meaning
reduc estim back core non-cor pressur reduc
ep ep account
continu cordi pressur larger-than-expect pharma price headwind
custom drug price higher tax rate particular one small off-set
lower share count base lower buy-back price also reduc po
equat ep estim unchang
upcom event catalyst
import near-term event well group dc-relat
first press confer drug price presid trump/hh secretari
hous opiod hear garner widespread attent given
import topic separ anoth catalyst iqvia mid-month
prescript updat may final commentari price either buysid
sell-side dynam crucial group sentiment
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug medic product
two-third profit pharmaceut
busi nearli one-third medic
support retail/mail/hospital/physician client
well drug manufactur medic busi
manufactur portfolio medic
product distribut brand-nam product
hospit physician compani base
under-perform rate driven increasingli
competit market compani core
busi pharmaceut medic devic
limit near-term offset think market
pharmaceut distribut remain
challeng near term histor upsid driver
red oak sourc benefit slow
medic cordi platform like support
solid growth ex-u see price volum
note earn call
disappoint cordi perform mask quarter creat higher non-gaap
tax rate adjust ep would cordi tax issu alon
effect tax rate result neg impact adjust ep
relat current forecast result
cordi true-up requir ytd adjust rel
book adjust relat higher anticip
increas effect tax rate
weaker expect cordi perform higher inventori
reserv major contributor higher expect tax rate
overal pharma perform better expect
strong perform red oak enough off-set gener
strong flu season provid upsid
brand inflat track gener line expect
signific renew quarter
extend expand contract optum end
optum custom sinc aug
expect cordi path profit growth end
revenu growth ytd non-u
cordi challeng persist
inventori challeng one biggest issu
cordi brand product includ exam glove add challeng
forecast modest
earli divestur china busi reflect
signific impact
custom initi re-pric optum
account half
challeng previous expect
tailwind patient recoveri red oak tax reform
signific headwind includ cordi custom re-pric loss
pharmerica continu gener deflat
see modest growth base updat
guidanc provid specif guidanc call
capit deploy strategi remain
cordi perform result abl take xxx
expect see tax rate declin go forward
gener price expect finish mid-to high singl digit
slightli higher origin expect seen moder
deflat vs last year last quarter moder fast
buysid gener price didnt see materi impact yet
could pressur
optum re-pric pressur re-pric client
larger normal custom re-pric next year
renew look partner custom front includ
consum health brand gener privat label product
look opportun addit volum exchang price
size scope cordi issu
inventori reserv much difficult outsid us
cordi busi
go evalu necessari countri
breadth product believ compet effect outsid
us
roll-out project solut roll one last quarter drove
inventori write-off go roll would provid
visibl inventori
inventori system place would better
compani roll first system larg inventori write-
quarter creat signific hit medic
exam glove continu challeng larg volum
commod type product lot downstream fix contract
medtron patient recoveri busi go well piec
us littl concern inventori reserv visibl
patient recoveri busi gener dont expir date
lesser program vs cordi product inventori challeng
biggest challeng cah system get inventori
visibl consign inventori work
red oak continu tailwind
gener deflat red oak outperform
client invest previous talk
relat repric relat cordi
relat tax compon spent
vast major alreadi spend get spent
price object ep multipl five-year
averag discount incorpor margin price pressur
pharmaceut segment slow brand inflat increas competit
downstream independ buy group discount medic segment
incorpor grow risk non-tradit distributor
upsid risk po potenti volum pickup increas buyside/sellsid
spread faster-than-expect contribut recent acquir medic
busi capit deploy downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market lack
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
